ADCI National Institutes of Health.
ADCI is an NMDA antagonist and a sodium channel antagonist which is under development by Neurogen and Wyeth-Ayerst as a potential treatment for epilepsy, seizures and stroke. Wyeth-Ayerst filed an IND with the US FDA on 24 June 1998 in preparation for phase II human clinical trials of ADCI, which are planned to begin in the US later in the year. A phase I study, conducted by Wyeth-Ayerst in France, found ADCI to be well tolerated across a broad dose range, with an acceptable pharmacokinetic profile. Further phase I testing in the US is expected in 1998 [267290]. Neurogen in-licensed ADCI from the National Institutes of Health in 1992, and subsequently out-licensed the compound to Wyeth in November 1996 [195049,226807]. ADCI is a mild NMDA antagonist and a use-dependent blocker of voltage-gated sodium channels, the combined effect of which, in preclinical studies, has been improved efficacy in the treatment of epileptic seizures. In animal models, ADCI has demonstrated a broad spectrum of anticonvulsant activity, coupled with a low incidence of side-effects [226807].